Search research articles
Contact Us
Filters
Showing results (141-150 of 153) with videos related to
Page
of 16
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 22, 2013
Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial
Lillian L Siu, Jeremy D Shapiro, Derek J Jonker, et al.
Clinical Colorectal Cancer
|
November 23, 2018
Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study
Jeremy D Shapiro, Subotheni Thavaneswaran, Craig R Underhill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 13, 2013
PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17
Christos S Karapetis, Derek Jonker, Manijeh Daneshmand, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 27, 2016
Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study
Eva Segelov, Subotheni Thavaneswaran, Paul M Waring, et al.
The Lancet. Oncology
|
December 17, 2021
Sotorasib for previously treated colorectal cancers with KRAS<sup>G12C</sup> mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial
Marwan G Fakih, Scott Kopetz, Yasutoshi Kuboki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 6, 2015
Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer
Marc Peeters, Kelly S Oliner, Timothy J Price, et al.
The New England Journal of Medicine
|
June 7, 2021
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
Ferdinandos Skoulidis, Bob T Li, Grace K Dy, et al.
JCO Precision Oncology
|
October 5, 2020
Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial
Elisa Fontana, Gift Nyamundanda, David Cunningham, et al.
International Journal of Cancer
|
September 28, 2020
Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies
Jeanne Tie, Joshua D Cohen, Serigne N Lo, et al.
Asia-Pacific Journal of Clinical Oncology
|
September 5, 2020
Young-onset colorectal cancer is associated with a personal history of type 2 diabetes
Reger R Mikaeel, Erin L Symonds, James Kimber, et al.
Page
of 16
Search research articles
Search
Showing results (141-150 of 153) with videos related to
Sort By:
Page
of 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 22, 2013
Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial
Lillian L Siu, Jeremy D Shapiro, Derek J Jonker, et al.
Clinical Colorectal Cancer
|
November 23, 2018
Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study
Jeremy D Shapiro, Subotheni Thavaneswaran, Craig R Underhill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 13, 2013
PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17
Christos S Karapetis, Derek Jonker, Manijeh Daneshmand, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 27, 2016
Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study
Eva Segelov, Subotheni Thavaneswaran, Paul M Waring, et al.
The Lancet. Oncology
|
December 17, 2021
Sotorasib for previously treated colorectal cancers with KRAS<sup>G12C</sup> mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial
Marwan G Fakih, Scott Kopetz, Yasutoshi Kuboki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 6, 2015
Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer
Marc Peeters, Kelly S Oliner, Timothy J Price, et al.
The New England Journal of Medicine
|
June 7, 2021
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
Ferdinandos Skoulidis, Bob T Li, Grace K Dy, et al.
JCO Precision Oncology
|
October 5, 2020
Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial
Elisa Fontana, Gift Nyamundanda, David Cunningham, et al.
International Journal of Cancer
|
September 28, 2020
Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies
Jeanne Tie, Joshua D Cohen, Serigne N Lo, et al.
Asia-Pacific Journal of Clinical Oncology
|
September 5, 2020
Young-onset colorectal cancer is associated with a personal history of type 2 diabetes
Reger R Mikaeel, Erin L Symonds, James Kimber, et al.
Page
of 16